Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02668276 · ClinicalTrials.gov registry record · NA
Engaging Newly Diagnosed Men About Cancer Treatment Options
A NA study, sponsored by University of Illinois at Chicago.
- Completed
- Registry status
- NA
- Development phase
- 200
- Enrollment target
NCT02668276 is a NA study that has completed, run by University of Illinois at Chicago. The registered enrollment target is 200 participants.
The verdict
NCT02668276, a NA study, has completed, sponsored by University of Illinois at Chicago.
- COMPLETED
- Registry status
- NA
- Development phase
- 200 participants
- Enrollment target
Study Summary
This research is being done to better understand how a new lab test called the Oncotype DX Prostate Cancer Assay may impact what treatment men decide to get and how they feel and think about their choice of treatment. The study will compare men who receive this new lab test with men who receive the usual counseling given to men after they get a new diagnosis of prostate cancer. Prostate cancer is sometimes slow-growing and sometimes fast-growing. Healthcare providers are searching for better ways to predict how each tumor will behave so that each man can make a better decision about when to receive treatment. The Oncotype DX lab test uses leftover prostate biopsy tissue to generate a Genomic Prostate Score (GPS). The GPS is related to the risk of a fast-growing cancer being discovered if surgery is performed to remove a man's prostate. The goal of this study is to find out if this test helps men when they are deciding how their prostate cancer will be treated. Treatment options include surgery to remove the prostate, radiation therapy, or an approach called "active surveillance" in which there is no immediate therapy and the tumor is watched using prostate specific antigen (PSA) tests and repeat biopsies.
Interventions
- OTHER Standard NCCN counseling
- OTHER Standard NCCN counseling and Oncotype DX results
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 200 participants |
| Start Date | 2016-04 |
| Est. Completion | 2019-08 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02668276
The ClinicalTrials.gov registry entry for NCT02668276 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 200 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Illinois at Chicago, which has 430 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Standard NCCN counseling is the first listed.
NCT02668276 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02668276 about?
NCT02668276 is a clinical study titled "Engaging Newly Diagnosed Men About Cancer Treatment Options". This research is being done to better understand how a new lab test called the Oncotype DX Prostate Cancer Assay may impact what treatment men decide to get and how they feel and think about their choice of treatment. The study will compare men who receive this new lab test with men who receive the ...
What is the current status of trial NCT02668276?
This trial is currently completed. It is a NA study. The enrollment target is 200 participants. The study started on 2016-04. Estimated completion is 2019-08.
What interventions are being tested in trial NCT02668276?
The interventions under investigation include: Standard NCCN counseling (OTHER), Standard NCCN counseling and Oncotype DX results (OTHER).
Who is sponsoring clinical trial NCT02668276?
This trial is sponsored by University of Illinois at Chicago, which has 430 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.